PharmaFocus Today – Page 13 – media

Gan & Lee Pharmaceuticals and Hillhouse Capital have reached a strategic cooperation agreement to optimize resource allocation and explore cooperation opportunities.

Shanghai Securities News China Securities(Reporter Zhang Xue) On November 10, Gan & Lee Pharmaceuticals…The company announced the transfer of its controlling stake in its wholly-owned subsidiary, GanGan Medical Technology Jiangsu Co., Ltd. (hereinafter referred to as “GanGan Jiangsu”), to Hillhouse Capital. Founded in 2017, GanGan Jiangsu is an innovation-driven medical technology company specializing in the research and development and production of high-quality drug delivery devices. Leveraging its strong pharmaceutical background and rigorous quality system, the company has established a comprehensive quality management and regulatory compliance system that meets international standards. Its products have obtained certifications from the U.S. Food and Drug Administration (FDA) and the European Union’s CE MDR (European Union Medical Device Registration System).(Regulations) certification. As the transferee, Hillhouse Capital has long focused on investments in the healthcare sector, possessing comprehensive industry chain insights and resource integration capabilities. Leveraging Hillhouse’s extensive experience in healthcare industry operations and value enhancement, ...
- Source: drugdu
- 87
- November 11, 2025
Sinovac Biotech’s GB12 project has been included in Shenzhen’s strategic emerging industries support plan.

Shanghai Securities News China Securities(Reporter Zhao Binbin) On November 10, this reporter learned from Sinovac Biotech…It has been learned that the innovative drug developed by the company’s wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd.The GB12 project, “Key Technology Breakthrough for AI-Generated IL-4R/IL-31 Bispecific Antibody Innovative Drugs ,” has been included in the list of projects proposed for funding under the first batch of strategic emerging industries support plans of the Shenzhen Development and Reform Commission in 2025. This project aims to develop a bispecific antibody drug for atopic dermatitis (AD). The drug targets both the IL-4R and IL-31 pathways, targeting both inflammation and itching simultaneously. The project plans to submit new drug clinical trial applications in both China and the United States in the future. https://finance.eastmoney.com/a/202511103560094614.html
- Source: drugdu
- 80
- November 11, 2025
CanSino Biologics and Panru Biotech sign licensing agreement to expand the application prospects of the three-component LNP delivery system

Shanghai Securities News China Securities(News from Nian Yue, reporter Zhang Xue) On the 10th, this reporter learned from CanSino Biologics…It has been learned that CanSino Biologics (Shanghai) Co., Ltd., a subsidiary of the company, recently signed a licensing agreement with Panru Biotechnology (Tianjin) Co., Ltd. (“Panru Biotechnology”), licensing its independently developed novel three-component lipid nanoparticle delivery system (ISL-3C-LNP) to Panru Biotechnology to expand its application prospects. CanSino stated that this licensing cooperation marks another important milestone for the company in the field of mRNA delivery technology, and will bring in more than 100 million yuan in revenue in the future, including upfront payments and milestone payments. 　　According to the agreement, Panru Biotech, upon obtaining authorization, can use ISL-3C-LNP as the core LNP lipid for the global research, development, production, and commercialization of its therapeutic prostate cancer mRNA vaccine (PRBT001 injection). It is understood that PRBT001 injection possesses completely independent intellectual ...
- Source: drugdu
- 91
- November 11, 2025
Influenza vaccine components are updated annually to match seasonal epidemic strains

At present, the vaccine compatibility of the H3N2 subtype influenza virus has further improved compared to previous years, and the compatibility of the H1N1 and B influenza viruses is even higher. ”On November 10th, at a press conference held by the National Bureau of Disease Control and Prevention, Wang Dayan, a researcher at the Institute of Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention, answered a question from a Science and Technology Daily reporter about the preventive effect of influenza vaccines, stating that the proportion of epidemic strains with antigenicity similar to vaccine strains exceeded 95%. In response to the misconception among a small portion of the public that the flu virus is constantly mutating and cannot be prevented even with vaccination, Wang Dayan made it clear that although the flu virus is prone to mutation, the flu vaccine will be updated annually to ...
- Source: drugdu
- 92
- November 11, 2025
Preclinical evidence supports sotagliflozin’s superior efficacy in attenuating salt-induced kidney damage

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects. In the kidney, SGLT2 reabsorbs approximately 97% offiltered glucose in the S1 and S2 segments of the proximal tubule, while SGLT1reabsorbs the remainder in the S3 segment. In research conducted in rats, investigators found that dual inhibition of SGLT1 and SGLT2 more effectively reduces salt-sensitive hypertension and kidney injury than SGLT2 inhibition alone. The findings will be presented at ASN Kidney Week 2025 November 5–9. Salt-sensitive hypertension-elevated blood pressure due to excess salt consumption- affects nearly half of individuals with high blood pressure and substantially contributes to kidney disease, cardiovascular complications, and progression to kidney failure. When researchers compared selective SGLT2 inhibition (through treatment with dapagliflozin) with dual SGLT1/2 inhibition(through treatment with sotagliflozin) in a well-established rat model of salt-induced hypertension and chronic kidney disease, they found that both drugs had ...
- Source: drugdu
- 90
- November 10, 2025
Infant Botulism in 10 US States Linked to Formula Being Recalled

Federal and state health officials are investigating 13 cases in 10 U.S. states of infant botulism linked to baby formula that is being recalled Federal and state health officials are investigating 13 cases in 10 states of infant botulism linked to baby formula that was being recalled, authorities said Saturday. ByHeart Inc. agreed to begin recalling two lots of the company’s Whole Nutrition Infant Formula, the Food and Drug Administration said in a statement. All 13 infants were hospitalized after consuming formula from two lots: 206VABP/251261P2 and 206VABP/251131P2. The cases occurred in Arizona, California, Illinois, Minnesota, New Jersey, Oregon, Pennsylvania, Rhode Island, Texas and Washington. No deaths were reported. The FDA said it was investigating how the contamination happened and whether it affected any other products. Available online and through major retailers, the product accounted for an estimated 1% of national formula sales, according to the Centers for Disease Control ...
- Source: drugdu
- 78
- November 10, 2025
Innovative Autoimmune Drug to Make its International Academic Debut at CS2015

　China Securities Intelligent Finance News: CStone Pharmaceuticals-B (02616) announced on the morning of November 7th that it will present its pipeline drug CS2015 (OX40L/TSLP bispecific antibody) in the field of autoimmune and inflammation for the first time at the 2025 American Academy of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting through electronic posters and oral presentations. This will be the drug’s first appearance at an international academic conference. 　　According to the announcement, CS2015 employs an asymmetric molecular structure, simultaneously targeting two key inflammatory regulators, OX40L and TSLP, and utilizes a mutant Fc to prolong its circulating half-life, supporting long-term dosing intervals. Preclinical studies have shown that this molecule can potently inhibit inflammatory signaling pathways, exhibiting rapid reduction in skin lesions, decreased immune cell infiltration, and relief of itching in animal models of atopic dermatitis. 　　The announcement indicates that, in terms of drug metabolism, CS2015 exhibits excellent pharmacokinetic characteristics in ...
- Source: drugdu
- 147
- November 8, 2025
Recombinant Human Nerve Growth Factor SMR001 Eye Drops Approved for Phase III Clinical Trials

　　China Securities Intelligent Finance ST Weiming(002581) announced on November 7 that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has independently developed a Class I innovative drug.The Phase III pivotal registration clinical trial of recombinant human nerve growth factor SMR001 eye drops for the treatment of moderate to severe dry eye disease recently received approval from the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University, the lead institution, marking the official commencement of the project. 　　The announcement stated that SMR001 eye drops are a key innovative ophthalmic biological drug developed by the company. Utilizing a Chinese hamster ovary cell (CHO) expression system, it is the first domestically produced eye drop formulation with recombinant human nerve growth factor as its active ingredient. This product, by repairing damaged corneal nerves and promoting epithelial regeneration, is expected to become a novel treatment option for moderate to severe dry eye syndrome. ...
- Source: drugdu
- 151
- November 8, 2025
Targeting Unmet Clinical Needs and Strengthening Innovation and International Development Strategies

　　China Securities Journal (Reporter Li Mengyang) – Recently, Henlius Biotech officially announced key updated data on its PD-L1 ADC (antibody-drug conjugate) HLX43 for the treatment of non-small cell lung cancer (NSCLC). This release integrates for the first time the results of the product’s international multicenter Phase II clinical trial, further validating its global clinical value. Simultaneously, the company also announced the latest follow-up data from a Phase II dose-finding study of its independently developed recombinant anti-EGFR monoclonal antibody HLX07, in combination with the anti-PD-1 monoclonal antibody H, slulimab, for first-line treatment of EGFR-high expressing advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). 　　”Currently, we invest most of our commercial revenue into the research and development of innovative pipeline products. The company is continuously advancing the development of core innovative products such as H-drug Hanseo and PD-L1 ADC HLX43,” said Zhu Jun, Executive Director and CEO of Henlius Biotech, in ...
- Source: drugdu
- 162
- November 8, 2025
GSK calls for the establishment of a standardized national systemic lupus erythematosus (SLE) diagnosis and treatment system to help improve the prognosis of lupus patients.

　　At the 8th China International Import ExpoAt the China International Import Expo (hereinafter referred to as “CIIE”), GlaxoSmithKlineGSK successfully invited several senior experts, scholars, and non-profit partners in the field of rheumatology and immunology to gather together to exchange ideas on topics such as disease awareness, patient support, and chronic disease management of systemic lupus erythematosus (SLE). The aim was to improve public scientific understanding, improve the living environment of patients, and help patients regain confidence in life. Leveraging the powerful enabling effect of the China International Import Expo 　　Data shows that systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disease that can cause damage to multiple organs and tissues, including the kidneys, cardiovascular system, lungs, digestive system, blood system, and eyes, and significantly increases the risk of death. Currently, there are over one million lupus patients in China, primarily women of childbearing age. With the continuous improvement ...
- Source: drugdu
- 113
- November 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.